Junqin Bi
Liming Bao
aDepartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200032, China
bCenter for Clinical Molecular Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400065, China
cDepartment of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth College, Lebanon, NH 03756, USA
More InformationCorresponding author: E-mail address: Liming.Bao@Dartmouth.edu (Liming Bao)
Received Date: 2017-09-09
Accepted Date:2017-11-25
Rev Recd Date:2017-11-24
Available Online: 2018-02-05 Publish Date:2018-02-20
Abstract
Abstract
Circulating cell-free tumor DNA (ctDNA) in the blood is DNA released from apoptotic, circulating, and living tumor cells. ctDNA is about 140 nt in length and has a half-life of about 1.5?h. ctDNA analysis provides a noninvasive means to assess the genetic profile of cancer in real time. With the advent of molecular technologies, including digital PCR and massively parallel sequencing (MPS), ctDNA analysis has shown promise as a highly sensitive and specific alternative to conventional tissue biopsy in cancer detection, longitudinal monitoring, and precision therapy. This review provides an overview of the latest development in our understanding of the biologic characteristics, detection methodologies, and potential clinical implications of ctDNA, as well as the challenges in translating ctDNA analysis from the research arena to patient care.Keywords: ctDNA,
Cancer genetics,
Genetic profile,
Liquid biopsy,
Precision therapy
PDF全文下载地址:
http://www.jgenetgenomics.org/article/exportPdf?id=1616d8c8-95a6-4926-8934-2b126fb6b0f7&language=en
